Biopharma companies are accelerating their agile transformation to achieve launch excellence – see our previous article in September 2025 PME, Driving launch excellence through agile transformation. However, this alone is no longer sufficient. Many organisations have already begun integrating AI into select pre-launch and launch processes.
The companies that will lead going forward are aiming for ‘AAA launch excellence’ – agile, adaptive, and agentic. They are evolving towards continuous learning models characterised by real-time sensing, faster decision-making and swift execution. This approach helps reduce uncertainty, enhance learning on investment (LOPI) and capture value from optionality in an increasingly complex and unpredictable environment.
Imagine a future where a launch plan is no longer static, but a living system – one that incorporates event-driven workflows, self-adjusting sequences and, over time, an increasing number of AI agent-triggered actions. Event-driven workflows may respond to external signals, such as competitor product data performing better than anticipated, or to internal developments, such as evidence for follow-on indications diverging from the base case assumptions.
AI agent-triggered actions represent the next frontier. Real-time insights from healthcare professionals (HCPs), for instance can dynamically inform risks or upsides relative to the base case, enabling continuous refinement of forecasts and more responsive decision-making.
